Forum Topic News
  • Conversation: Final NICE green light for Ipsen’s Cometriq

    • March 28, 2018 12:58 PM BST
    • Final NICE green light for Ipsen’s Cometriq

      Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
      The National Institute for Health and Care Excellence has issued guidelines recommending the drug as an option for treating progressive MTC in adults with unresectable, locally advanced or metastatic disease.
      Read more: http://www.pharmatimes.com/news/final_nice_green_light_for_ipsens_cometriq_1229604

Add Reputation

Do you want to add reputation for this member by this post?

or cancel